United States Biotechnology & Medical Research

Bio-Techne Corp (TECH)

Track

Bio-Techne Corp has seen 640,803.57 USD in insider selling over the past 90 days, with no recorded insider purchases. These transactions occurred following the company's May 2026 earnings report. The stock has experienced a 31.8% price increase over the last three months, currently trading near its 52-week high.
Ticker: TECH Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Bio-Techne Corp. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 8 May 2026
Value US$3,566,371.04 | Price 62.17 | Shares 13,441 (+25.1%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-12 2026-05-08 S Sale
2.6
Herr Amy E.
Non-Executive Director
13,441 +25.1%
62.17
US$3,566,371 		13,441 +25.1% 62.17 US$3,566,371
2026-05-08 2026-05-08 PrS Proposed sale
2.6
JOSHUA MOLHO

Director

Non-Executive Director
70,690
183.33
US$3,652,312 		70,690 183.33 US$3,652,312
2026-02-19 2026-02-17 S Sale
2.6
Herr Amy E.
Non-Executive Director
50,417 -6.3%
172.89
US$3,297,005 		50,417 -6.3% 172.89 US$3,297,005
2026-02-17 2026-02-17 PrS Proposed sale
2.6
JOSHUA MOLHO

Director

Non-Executive Director
1,976
59.11
US$116,791 		1,976 59.11 US$116,791
2025-08-27 2025-08-25 S Sale
3.0
Nusse Roeland
Non-Executive Director
17,040 -27.7%
56.36
US$960,388 		17,040 -27.7% 56.36 US$960,388
2025-08-27 2025-08-25 S Sale
1.7
BAUMGARTNER ROBERT V
Non-Executive Director
17,040 -27.5%
56.21
US$957,818 		17,040 -27.5% 56.21 US$957,818
2025-08-25 2025-08-25 PrS Proposed sale
3.0
ROELAND NUSSE

Director

Non-Executive Director
17,040
56.36
US$960,388 		17,040 56.36 US$960,388
2025-08-25 2025-08-25 PrS Proposed sale
1.7
ROBERT V. BAUMGARTNER4731 BONITA BAY BOULEVARD

Director

Non-Executive Director
17,040
56.21
US$957,849 		17,040 56.21 US$957,849
2025-06-11 2025-06-09 S Sale
2.6
Herr Amy E.
Non-Executive Director
1,280 -39.3%
49.77
US$63,705 		1,280 -39.3% 49.77 US$63,705
2025-06-09 2025-06-09 PrS Proposed sale
2.6
JOSHUA MOLHO

Officer

Officer
1,280
49.77
US$63,705 		1,280 49.77 US$63,705
2025-02-18 2025-02-14 S Sale
2.6
Herr Amy E.
Non-Executive Director
1,860 -48.5%
65.96
US$122,691 		1,860 -48.5% 65.96 US$122,691
2025-02-14 2025-02-14 PrS Proposed sale
2.6
JOSHUA MOLHO

Domestic Partner of Director

Non-Executive Director
1,860
65.96
US$122,691 		1,860 65.96 US$122,691
2025-01-29 2025-01-27 S Sale
3.7
Kelderman Kim

Chief Executive Officer

Executive Director
1,661 -4.1%
77.95
US$129,480 		1,661 -4.1% 77.95 US$129,480
2025-01-29 2025-01-27 S Sale
3.7
Kelderman Kim

Chief Executive Officer

Executive Director
11,731 -22.4%
77.19
US$905,533 		11,731 -22.4% 77.19 US$905,533
2025-01-27 2025-01-27 PrS Proposed sale
3.7
KIM KELDERMAN

Director; Officer

Executive Director
13,392
77.05
US$1,031,854 		13,392 77.05 US$1,031,854
2024-08-12 2024-08-08 S Sale
1.7
BAUMGARTNER ROBERT V
Non-Executive Director
16,000 -26.9%
72.10
US$1,153,664 		16,000 -26.9% 72.10 US$1,153,664
2024-08-08 2024-08-08 PrS Proposed sale
1.7
ROBERT V. BAUMGARTNER

Director

Non-Executive Director
16,000
72.10
US$1,153,664 		16,000 72.10 US$1,153,664
2024-05-16 2024-05-14 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
4,000 -9.9%
83.84
US$335,377 		4,000 -9.9% 83.84 US$335,377
2024-05-14 2024-05-14 PrS Proposed sale
3.4
JOHN L HIGGINS

Director

Non-Executive Director
4,000
83.84
US$335,377 		4,000 83.84 US$335,377
2024-03-11 2024-03-07 S Sale
3.0
Nusse Roeland
Non-Executive Director
10,400 -19.4%
76.98
US$800,627 		10,400 -19.4% 76.98 US$800,627
2024-03-07 2024-03-07 PrS Proposed sale
3.0
Nusse Roeland

Director

Non-Executive Director
10,400
76.98
US$800,626 		10,400 76.98 US$800,626
2023-09-01 2023-08-30 S Sale
3.0
Nusse Roeland
Non-Executive Director
8,939 -14.7%
80.32
US$717,959 		8,939 -14.7% 80.32 US$717,959
2023-08-30 2023-08-30 PrS Proposed sale
3.0
ROELAND NUSSE

Director

Non-Executive Director
8,939
80.32
US$717,959 		8,939 80.32 US$717,959
2023-07-25 2023-07-21 PlS Planned sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
80,000 -6.0%
88.36
US$7,069,024 		80,000 -6.0% 88.36 US$7,069,024
2023-07-21 2023-07-21 PrS Proposed sale
2.8
Kummeth Charles R.

Officer

Officer
80,000
88.36
US$7,069,024 		80,000 88.36 US$7,069,024
2023-06-09 2023-06-07 S Sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
322 -0.0%
83.00
US$26,726 		322 -0.0% 83.00 US$26,726
2023-06-06 2023-06-06 PrS Proposed sale
2.8
Charles Kummeth

Officer

Officer
50,000
83.00
US$4,150,000 		50,000 83.00 US$4,150,000
2022-12-09 2022-12-08 S Sale
2.8
Furlow Brenda S.

SVP - GENERAL COUNSEL

Officer
7,450 -22.2%
82.12
US$611,810 		7,450 -22.2% 82.12 US$611,810
2022-12-09 2022-12-07 S Sale
2.8
Furlow Brenda S.

SVP - GENERAL COUNSEL

Officer
800 -3.0%
82.01
US$65,605 		800 -3.0% 82.01 US$65,605
2022-08-12 2022-08-11 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
8 -0.1%
380.71
US$3,046 		8 -0.1% 380.71 US$3,046
2022-08-12 2022-08-11 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
504 -8.4%
385.47
US$194,277 		504 -8.4% 385.47 US$194,277
2022-08-12 2022-08-10 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
992 -14.2%
380.15
US$377,112 		992 -14.2% 380.15 US$377,112
2022-08-12 2022-08-10 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
100 -1.4%
374.90
US$37,490 		100 -1.4% 374.90 US$37,490
2022-08-12 2022-08-10 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
900 -11.2%
373.99
US$336,593 		900 -11.2% 373.99 US$336,593
2022-06-09 2022-06-08 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
600 -11.5%
366.09
US$219,654 		600 -11.5% 366.09 US$219,654
2022-06-09 2022-06-07 S Sale
2.8
Kummeth Charles R.

CHIEF EXECUTIVE OFFICER

Executive Director
5,104 -2.5%
365.00
US$1,862,960 		5,104 -2.5% 365.00 US$1,862,960
2022-06-09 2022-06-07 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
1,000 -17.8%
364.31
US$364,310 		1,000 -17.8% 364.31 US$364,310
2022-05-11 2022-05-10 B Purchase
1.7
BAUMGARTNER ROBERT V
Non-Executive Director
300 +3.1%
352.55
US$105,765 		300 +3.1% 352.55 US$105,765
2021-11-23 2021-11-19 S Sale
3.7
Kelderman Kim

Pres. Diagnostics & Genom

Officer
400 -100.0%
505.78
US$202,313 		400 -100.0% 505.78 US$202,313
2021-11-23 2021-11-19 S Sale
3.7
Kelderman Kim

Pres. Diagnostics & Genom

Officer
100 -20.0%
503.76
US$50,376 		100 -20.0% 503.76 US$50,376
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
401 -23.3%
506.24
US$203,002 		401 -23.3% 506.24 US$203,002
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
2,535 -59.6%
505.49
US$1,281,407 		2,535 -59.6% 505.49 US$1,281,407
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
8,989 -67.9%
504.39
US$4,533,985 		8,989 -67.9% 504.39 US$4,533,985
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
9,043 -40.6%
503.61
US$4,554,137 		9,043 -40.6% 503.61 US$4,554,137
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
4,054 -15.4%
502.77
US$2,038,221 		4,054 -15.4% 502.77 US$2,038,221
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
400 -1.5%
505.01
US$202,002 		400 -1.5% 505.01 US$202,002
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
537 -2.0%
504.14
US$270,725 		537 -2.0% 504.14 US$270,725
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
300 -1.1%
502.99
US$150,897 		300 -1.1% 502.99 US$150,897
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
200 -0.7%
504.78
US$100,956 		200 -0.7% 504.78 US$100,956
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
700 -2.5%
504.09
US$352,860 		700 -2.5% 504.09 US$352,860
2021-11-03 2021-11-02 PlS Planned sale
2.4
Hippel James

Chief Financial Officer

Officer
200 -1.8%
525.10
US$105,020 		200 -1.8% 525.10 US$105,020
2021-11-03 2021-11-01 PlS Planned sale
2.4
Hippel James

Chief Financial Officer

Officer
943 -8.1%
528.55
US$498,427 		943 -8.1% 528.55 US$498,427
2021-11-03 2021-11-01 PlS Planned sale
2.4
Hippel James

Chief Financial Officer

Officer
1,433 -10.9%
527.50
US$755,903 		1,433 -10.9% 527.50 US$755,903
2021-11-03 2021-11-01 PlS Planned sale
2.4
Hippel James

Chief Financial Officer

Officer
2,880 -18.0%
526.50
US$1,516,321 		2,880 -18.0% 526.50 US$1,516,321
2021-11-03 2021-11-01 PlS Planned sale
2.4
Hippel James

Chief Financial Officer

Officer
3,566 -18.2%
525.61
US$1,874,318 		3,566 -18.2% 525.61 US$1,874,318
2021-11-01 2021-10-29 PlS Planned sale
2.4
Hippel James

Chief Financial Officer

Officer
662 -5.8%
525.23
US$347,704 		662 -5.8% 525.23 US$347,704
2021-11-01 2021-10-28 PlS Planned sale
2.4
Hippel James

Chief Financial Officer

Officer
100 -0.9%
525.18
US$52,518 		100 -0.9% 525.18 US$52,518
2021-09-02 2021-08-31 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
1,538 -53.9%
503.07
US$773,728 		1,538 -53.9% 503.07 US$773,728
2021-09-02 2021-08-31 S Sale
2.8
Furlow Brenda S.

SVP - General Counsel

Officer
3,108 -29.0%
506.12
US$1,573,011 		3,108 -29.0% 506.12 US$1,573,011
2021-09-02 2021-08-31 S Sale
2.8
Furlow Brenda S.

SVP - General Counsel

Officer
1,569 -12.8%
505.26
US$792,755 		1,569 -12.8% 505.26 US$792,755
2021-09-02 2021-08-31 S Sale
2.8
Furlow Brenda S.

SVP - General Counsel

Officer
323 -2.6%
503.24
US$162,546 		323 -2.6% 503.24 US$162,546
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
300 -2.7%
484.98
US$145,494 		300 -2.7% 484.98 US$145,494
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
300 -2.6%
483.62
US$145,085 		300 -2.6% 483.62 US$145,085
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
300 -2.6%
481.61
US$144,482 		300 -2.6% 481.61 US$144,482
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
700 -5.6%
480.66
US$336,462 		700 -5.6% 480.66 US$336,462
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
100 -0.8%
480.70
US$48,070 		100 -0.8% 480.70 US$48,070
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
1,300 -9.4%
479.96
US$623,954 		1,300 -9.4% 479.96 US$623,954
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
1,800 -11.5%
478.58
US$861,444 		1,800 -11.5% 478.58 US$861,444
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
5,200 -24.9%
477.69
US$2,484,002 		5,200 -24.9% 477.69 US$2,484,002
2021-06-21 2021-06-18 PlS Planned sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
326 -0.2%
450.37
US$146,821 		326 -0.2% 450.37 US$146,821
2021-06-21 2021-06-18 PlS Planned sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
2,583 -1.6%
449.09
US$1,159,999 		2,583 -1.6% 449.09 US$1,159,999
2021-06-21 2021-06-17 PlS Planned sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
109 -0.1%
452.13
US$49,282 		109 -0.1% 452.13 US$49,282
2021-06-21 2021-06-17 PlS Planned sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
1,050 -0.7%
451.54
US$474,117 		1,050 -0.7% 451.54 US$474,117
2021-06-21 2021-06-17 PlS Planned sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
1,698 -1.1%
450.39
US$764,762 		1,698 -1.1% 450.39 US$764,762
2021-06-21 2021-06-17 PlS Planned sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
6,732 -4.0%
449.35
US$3,025,024 		6,732 -4.0% 449.35 US$3,025,024
Explore more

More insider trading research around Bio-Techne Corp

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America